Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Tarsa Therapeutics is planning to submit a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for Ostora, an oral recombinant salmon calcitonin tablet for the treatment of postmenopausal osteoporosis, in the second half of 2012.
Subscribe to our email newsletter
The initiative follows a formal pre-NDA verification with the FDA that verified the results from Tarsa’s Phase III ORACAL trial and the requirements for regulatory approval.
The Phase III ORACAL trial has demonstrated the positive efficacy and safety results of oral calcitonin tablet in the treatment of postmenopausal osteoporosis.
Currently, Ostora is being evaluated in a one-year double-blind Phase II study in postmenopausal women who have low bone mass (osteopenia) and are at increased risk of fracture.
Under a licensing agreement with Unigene Laboratories, Tarsa is developing its Ostora oral calcitonin and attains exclusive development and worldwide commercialization rights to Unigene’s oral calcitonin product.
Tarsa CEO David Brand said the recent dialogue with the FDA was productive and they are on track to submit an NDA for Ostora as a treatment for postmenopausal osteoporosis in the second half of 2012.